Kitov Pharma to Present New Data on NT-219 Targeting Cancer Drug Resistance at the AACR Pancreatic Cancer: Advances in Scienc...
August 29 2019 - 8:30AM
Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a
clinical-stage company advancing first-in-class therapies to
overcome tumor immune evasion and drug resistance, today announced
that Kitov’s subsidiary, TyrNovo, will present new data at the
American Association for Cancer Research (AACR) Pancreatic Cancer:
Advances in Science and Clinical Care conference being held
September 6 – 9, 2019 in Boston.
The poster presentation will showcase new data
on NT-219, Kitov’s developmental first-in-class, small molecule,
dual inhibitor of the two common cancer resistance pathways STAT3
and IRS1/2. Kitov is advancing NT-219 primarily for the treatment
of recurrent and metastatic squamous cell carcinoma of head &
neck cancer (SCCHN) and exploring its potential in additional
oncology indications including pancreatic cancer.
Presentation Details:
Title: |
NT219, A Novel
Bi-specific Inhibitor of STAT3 and IRS1/2 Sensitized Resistant
Pancreatic Tumors to Gemcitabine and MEK inhibitor and Induced
Tumor Regression |
Session: |
Poster session
C |
Presenter: |
Hadas Reuveni,
Ph.D. |
Date: |
September 8,
2019 |
Time: |
4:00 p.m. – 6:30
p.m. ET |
Location: |
Westin Copley
Place, Boston, MA |
About the AACR Pancreatic Cancer: Advances in Science
and Clinical Care Conference
The conference will be the sixth AACR Special
Conference on pancreatic cancer. According to the U.S. National
Cancer Institute, pancreatic cancer will account for approximately
44,330 deaths in 2018 and is poised to become the third leading
cause of cancer deaths by 2030. As the field continues to grow, it
is imperative that researchers can interact, share data, and
discuss ideas to help reach the overall goal of improved treatment
for pancreatic cancer. The conference will showcase sessions on
tumor heterogeneity, immunology, prevention and early detection,
and novel treatment combinations, among others.
About Kitov Pharma
Kitov Pharma (Kitov Pharma Ltd.; NASDAQ/TASE:
KTOV) is a clinical-stage company advancing first-in-class
therapies to overcome tumor immune evasion and drug resistance, to
create successful long-lasting treatments for people with cancer.
Kitov’s oncology pipeline includes NT-219, a small molecule
targeting the novel cancer drug resistance pathways IRS1/2 and
STAT3. Kitov is currently advancing NT-219 in combination with
cetuximab as a third-line or second-line treatment option for the
treatment of recurrent and metastatic squamous cell carcinoma of
head & neck cancer (SCCHN). Kitov is also under contract to
acquire 100% of FameWave Ltd. which owns CM-24, a monoclonal
antibody blocking CEACAM1, a novel immune checkpoint that supports
tumor immune evasion and survival through multiple pathways. Kitov
will advance CM-24 as a combination therapy with anti-PD1
checkpoint inhibitors in a clinical collaboration agreement with
Bristol Myers Squibb (NYSE:BMY) in a planned Phase 1/2 clinical
trials to evaluate the combination of CM-24 with the PD-1 inhibitor
nivolumab (Opdivo®) for the treatment of non-small cell lung cancer
(NSCLC) All major closing conditions have been met other than
finalizing the tax ruling for the sellers and the issuance and
exchange of shares in the companies and the acquisition is expected
to close during the third quarter of 2019. Consensi, a
fixed-dose combination of celecoxib and amlodipine besylate, for
the simultaneous treatment of osteoarthritis pain and hypertension
was approved by the FDA for marketing in the U.S in May 2018 and is
expected to be launched in the U.S. at the end of 2019 by its
partner Coeptis Pharmaceuticals. Kitov has also partnered to
commercialize Consensi in China and South Korea.
The company is headquartered in Tel Aviv,
Israel. For more information, please visit
http://www.kitovpharma.com.
Forward-Looking Statements and Kitov's
Safe Harbor StatementCertain statements in this press
release that are forward-looking and not statements of historical
fact are forward-looking statements within the meaning of the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include, but are not
limited to, statements that are not statements of historical fact,
and may be identified by words such as “believe”, “expect”,
“intend”, “plan”, “may”, “should”, “could”, “might”, “seek”,
“target”, “will”, “project”, “forecast”, “continue” or “anticipate”
or their negatives or variations of these words or other comparable
words or by the fact that these statements do not relate strictly
to historical matters. You should not place undue reliance on these
forward-looking statements, which are not guarantees of future
performance. Forward-looking statements reflect our current views,
expectations, beliefs or intentions with respect to future events,
and are subject to a number of assumptions, involve known and
unknown risks, many of which are beyond our control, as well as
uncertainties and other factors that may cause our actual results,
performance or achievements to be significantly different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Important factors that could cause
or contribute to such differences include, among others, risks
relating to: the manner in which the parties to the transaction for
the acquisition of FameWave by Kitov plan to effect the closing of
the transaction; the expected benefits, synergies and costs of the
transaction; management plans relating to the transaction; the
expected timing of the completion of the transaction; the parties’
ability to complete the transaction considering the various closing
conditions; the plans, strategies and objectives of management for
future operations; product development for NT219 and CM-24; the
potential future financial impact of the transaction; and any
assumptions underlying any of the foregoing; the process by which
early stage products such as CM-24 could potentially lead to
an approved product is long and subject to highly significant
risks, particularly with respect to a joint development
collaboration; the fact that drug development and commercialization
involves a lengthy and expensive process with uncertain outcomes;
our ability to successfully develop and commercialize our
pharmaceutical products; the expense, length, progress and results
of any clinical trials; the lack of sufficient funding to finance
the clinical trials; the impact of any changes in regulation and
legislation that could affect the pharmaceutical industry; the
difficulty in receiving the regulatory approvals necessary in order
to commercialize our products; the difficulty of predicting actions
of the U.S. Food and Drug Administration or any other applicable
regulator of pharmaceutical products; the regulatory environment
and changes in the health policies and regimes in the countries in
which we operate; the uncertainty surrounding the actual market
reception to our pharmaceutical products once cleared for marketing
in a particular market; the introduction of competing products;
patents attained by competitors; dependence on the effectiveness of
our patents and other protections for innovative products; our
ability to obtain, maintain and defend issued patents with
protective claims; the commencement of any patent interference or
infringement action; our ability to prevail, obtain a favorable
decision or recover damages in any such action; and the exposure to
litigation, including patent litigation, and/or regulatory actions;
any continued uncertainty surrounding an investigation by the
Israel Securities Authority into our historical public disclosures
which was settled under an administrative enforcement proceeding,
and the potential impact of such investigation and settlement on
the trading of our securities or on our clinical, commercial and
other business relationships, or on receiving the regulatory
approvals necessary in order to commercialize our products, and
other factors that are discussed in our in our Annual Report on
Form 20-F for the year ended December 31, 2018 and in our other
filings with the SEC, including our cautionary discussion of risks
and uncertainties under ‘Risk Factors’ in our Registration
Statements and Annual Reports. These are factors that we believe
could cause our actual results to differ materially from expected
results. Other factors besides those we have listed could also
adversely affect us. Any forward-looking statement in this press
release speaks only as of the date which it is made. We disclaim
any intention or obligation to publicly update or revise any
forward-looking statement, or other information contained herein,
whether as a result of new information, future events or otherwise,
except as required by applicable law. You are advised, however, to
consult any additional disclosures we make in our reports to the
SEC, which are available on the SEC’s website, http://www.sec.gov
For further information, contact: Gil Efron Deputy CEO
& Chief Financial Officer +972-3-933-3121 ext.
#105 IR@kitovpharma.com
Media Inquiries:Darren Opland,
Ph.D.darren@lifescipublicrelations.com+1 646 627 8387
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Sep 2023 to Sep 2024